Cara Therapeutics Inc (CARA) CEO Derek T. Chalmers Sells 20,000 Shares

Share on StockTwits

Cara Therapeutics Inc (NASDAQ:CARA) CEO Derek T. Chalmers sold 20,000 shares of the firm’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $19.71, for a total transaction of $394,200.00. Following the completion of the sale, the chief executive officer now owns 1,031,392 shares in the company, valued at $20,328,736.32. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

NASDAQ CARA opened at $19.93 on Friday. Cara Therapeutics Inc has a 52-week low of $11.11 and a 52-week high of $22.29.

Cara Therapeutics (NASDAQ:CARA) last posted its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.02). The business had revenue of $2.87 million for the quarter, compared to the consensus estimate of $0.63 million. equities analysts expect that Cara Therapeutics Inc will post -1.98 EPS for the current year.

Institutional investors have recently modified their holdings of the company. Cornerstone Wealth Management LLC acquired a new stake in shares of Cara Therapeutics during the 2nd quarter valued at about $715,000. Wells Fargo & Company MN boosted its position in shares of Cara Therapeutics by 322.5% during the 1st quarter. Wells Fargo & Company MN now owns 84,697 shares of the biopharmaceutical company’s stock valued at $1,049,000 after acquiring an additional 64,651 shares in the last quarter. UBS Group AG boosted its position in shares of Cara Therapeutics by 359.1% during the 1st quarter. UBS Group AG now owns 178,260 shares of the biopharmaceutical company’s stock valued at $2,207,000 after acquiring an additional 139,436 shares in the last quarter. State of Wisconsin Investment Board boosted its position in shares of Cara Therapeutics by 38.0% during the 2nd quarter. State of Wisconsin Investment Board now owns 27,600 shares of the biopharmaceutical company’s stock valued at $529,000 after acquiring an additional 7,600 shares in the last quarter. Finally, Chescapmanager LLC boosted its position in shares of Cara Therapeutics by 10.6% during the 2nd quarter. Chescapmanager LLC now owns 1,164,431 shares of the biopharmaceutical company’s stock valued at $22,299,000 after acquiring an additional 111,498 shares in the last quarter. Institutional investors and hedge funds own 48.67% of the company’s stock.

Several analysts have issued reports on the stock. Needham & Company LLC raised their price target on shares of Cara Therapeutics from $23.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday, June 27th. BidaskClub lowered shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, July 31st. Stifel Nicolaus raised their price target on shares of Cara Therapeutics to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, May 23rd. ValuEngine upgraded shares of Cara Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 2nd. Finally, Zacks Investment Research lowered shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, July 24th. Four analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. Cara Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $25.86.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Featured Story: Using the New Google Finance Tool

Insider Buying and Selling by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply